---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135267"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:40:37.864492+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M

## Summary
- Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.
- Collaboration revenue $39.3M, up $21.4M YoY, driven by Kite Pharma agreement amendments.
- Net loss of $7.2M vs $27.3M in Q1 2023, an improvement of $20.1M.
- R&D expenses $32.3M (down $0.6M YoY); G&A expenses $22.7M (up $7.3M YoY) on higher personnel costs.

## SEC filing metadata
- accession: 0001193125-24-135267
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/0001193125-24-135267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/d837604d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135267
- JSON: https://secwatch.observer/filing/0001193125-24-135267.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135267.txt

## Key facts
- Earnings Releases
  Arcellx, Inc. reported for the first quarter ended March 31, 2024 results: revenue $39.3 million, net income Net loss was $7.2 million.
  - Period: for the first quarter ended March 31, 2024
  - Revenue: $39.3 million
  - Net income: Net loss was $7.2 million
  - Result: reported results
  source text: million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million. This increase was primarily driven by changes in estimated
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/0001193125-24-135267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.